Pharmacies to require more checks before selling weight-loss jabs

May Be Interested In:UEFA Champions League score predictions, picks for Tuesday, February 18: Get ready for draws-a-plenty


Annabel Rackham and Elena Bailey

Health reporters, BBC News

Getty Images Pictures of Ozempic and Wegovy pensGetty Images

Weight-loss jabs will now require stricter prescribing criteria for online pharmacies

Online pharmacies will now have to employ stricter checks to stop people who are already a healthy weight or have a history of eating disorders buying weight-loss jabs.

They will no longer be able to dispense the medication, sold under brand names such as Wegovy and Mounjaro, to patients who have just completed online questionnaires or sent photos.

In-person or video consultations will be required, to verify patient body mass index (BMI), along with information from GP or medical records.

And pharmacists failing to follow this new guidance could face enforcement action, including fitness-to-practise investigations or inspections, and conditions such as improvement plans, the General Pharmaceutical Council says.

High risk

The GPhC is worried about about both unsafe prescribing and potential supply issues, with some online pharmacies reportedly setting targets to process a certain number of prescriptions per hour.

And prescribers will be told to “actively” share with a patient’s GP information about what they are dispensing.

GPhC chief executive Duncan Rudkin said: “We know online pharmacy services can provide a very valuable service – but through our inspections and investigations, we’ve seen too many cases of medicines being supplied inappropriately online and putting people at risk.”

Weight-loss drugs are now classed as “high risk” medicines, requiring extra safeguards, and are offered on the NHS with very strict criteria.

Counterfeit products

Semaglutide and tirzepatide were first used to help type 2 diabetes patients regulate their blood-sugar levels.

But in the past three to four years, they started being prescribed as a weight-loss aide, leading to global shortages and counterfeit products.

Both are given as weekly injections via pre-filled pens self-administered into the upper arm, thigh or stomach.

And patients generally start on a low dose, which is gradually increased.

The drugs mimic the intestinal hormone glucagon-like peptide-1 (GLP-1), which is released after eating and typically makes people feel fuller.

Tirzepatide (Mounjaro) also affects the glucose-dependent insulinotropic polypeptide (GIP) hormone, which controls metabolism and helps regulate energy balance.

The first study into weight-loss drugs has found they can significantly improve heart health, with lower levels of heart attacks, stroke, heart failure and high blood pressure.

share Share facebook pinterest whatsapp x print

Similar Content

The Last Watch of 2024: The Films and Shows That Stole My Heart This Year - IGN
The Last Watch of 2024: The Films and Shows That Stole My Heart This Year – IGN
On political caricatures, “real” policies and the idea of public service
On political caricatures, “real” policies and the idea of public service
'Bungling Badenoch': Tory Leader Accused Of Planning To Cut State Pension
‘Bungling Badenoch’: Tory Leader Accused Of Planning To Cut State Pension
The 'Cosmos 2553' satellite was blasted through the atmosphere atop a Soyuz-2 rocket from Russia 's Plesetsk Cosmodrome in February 2022
Putin’s secret space weapon: Kremlin’s mysterious Cosmos 2553 satellite ‘is fitted with dummy warhead’ in ‘forerunner to nuke that could wipe out rival spacecraft and cause chaos on Earth’
Trip to Russia: Kent Hughes didn’t just go to observe Ivan Demidov
Trip to Russia: Kent Hughes didn’t just go to observe Ivan Demidov – Dose.ca
Bashar Assad’s fall: A major blow to Iran’s regional ambitions
Bashar Assad’s fall: A major blow to Iran’s regional ambitions
Frontpage Focus: The Day's Most Important Events | © 2025 | Daily News